Sensus Healthcare

SRTS

Market cap $52.6M

Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $3.31, moving 4.06% from the previous trading session.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Sensus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $3.45, representing a -2.82% change from its previous close.

Sensus Healthcare, Inc. (SRTS) concluded the recent trading session at $3.17, signifying a +2.26% move from its prior day's close.

NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. ("Sensus" or the "Company") (NASDAQ: SRTS).

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. ("Sensus" or the "Company") (NASDAQ: SRTS).

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that a study published in Dermatologic Therapy demonstrates the safety and efficacy of the Company's superficial radiotherapy (SRT) technology combined with punch excision to treat keloids. The article, titled “Efficacy of Punch Excision C.

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $3.15, representing a +1.29% change from its previous close.

NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Sensus Healthcare, Inc. ("Sensus" or the "Company") (NASDAQ: SRTS).